Hologic COO Named Chair of AdvaMedDx

AdvaMedDx today announced that Hologic Chief Operating Officer Eric Compton has been named chairman of the AdvaMedDx Board of Directors for a two-year term.
 
Compton served on the AdvaMedDx Board from 2012-2013 with Ortho Clinical Diagnostics, and from 2015 to the present with Hologic Inc..
 
“It is an honor to extend my tenure on the Board in this new position, particularly as AdvaMedDx continues to promote the critical role of diagnostic testing in achieving health care cost savings and better patient outcomes,” said Compton. “I look forward to working closely with the talented AdvaMedDx team and our diverse membership to advance sensible public policy that improves access to accurate, reliable and innovative medical technology and enables people to live longer, stronger and healthier lives.”
 
“AdvaMedDx is privileged to have Eric leading our board as chair,” said AdvaMed Chief Strategy Officer Andy Fish. “His experience and depth of knowledge in the diagnostics industry make him an excellent choice for this important position as we tackle the challenges of the next two years.”
 
Compton succeeds former Chairman and Cepheid CEO John Bishop.
 
“We’re grateful for the direction and guidance that John provided to AdvaMedDx during his chairmanship,” said Fish. “As one of the original, founding members of the Dx Board, John assumed leadership during a time of significant policy work by the association and shortly before the Protecting Access to Medicare Act was enacted, which included historic diagnostic test payment reforms. His steadfast commitment to the association’s work on diagnostic regulatory reform helped to lay a solid foundation for future progress.”
 
AdvaMedDx member companies produce advanced, in-vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, enable early detection of disease and reduce overall healthcare costs. Functioning as a division of AdvaMed, AdvaMedDx is the only multi-faceted policy organization that deals exclusively with issues facing in-vitro diagnostic companies both domestically in the United States and abroad.